VERU INC.
VERUNasdaqHealthcare · Pharmaceutical Preparations · WI · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | $16.9M | $16.3M | $39.4M | $61.3M | $42.6M |
| Operating income | −$24.8M | −$36.2M | −$93.8M | −$83.2M | $13.0M | −$14.7M |
| Net income | −$22.7M | −$37.8M | −$93.2M | −$83.8M | $7.4M | −$19.0M |
| Total assets | $29.8M | $60.4M | $50.0M | $136.1M | $178.1M | $51.5M |
| Total liabilities | $11.5M | $28.1M | $30.3M | $55.3M | $25.9M | $21.4M |
| Equity | $18.3M | $32.3M | $19.7M | $82.8M | $152.3M | $30.1M |
| EPS (diluted) | $-1.55 | $-2.80 | $-1.10 | $-1.05 | $0.09 | $-0.28 |
| Shares out. | 16.1M | 146.4M | 93.7M | 80.6M | 80.0M | 70.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −124.0%
- Return on assets
- −76.2%
- Return on capital (ROCE)
- −112.2%
- Liabilities / assets
- 38.6%
- Debt / equity
- 0.63×
- Book value / share
- $1.14
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -36.12distress
- Accruals / assets
- 24.5%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 15, 2024
- NT 10-Kmissed a reporting deadline ↗Jan 2, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Alyeska Investment Group, L.P.Passive (13G)Feb 17, 2026
- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Adage Capital Partners Gp, L.L.C.Passive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 592,671 | 9.1 | +2.7% |
| Apr 30, 2026 | 577,156 | 10.6 | -12.0% |
| Apr 15, 2026 | 656,045 | 12.0 | -2.2% |
| Mar 31, 2026 | 670,734 | 13.1 | -7.0% |
| Mar 13, 2026 | 721,163 | 12.0 | -1.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Director / officer change · Shareholder voteMar 13, 2026
- Results of operationsFeb 11, 2026
- Results of operationsDec 17, 2025
- Entered a material agreement · Other material eventOct 30, 2025
- Terminated a material agreementSep 26, 2025
- Other material eventAug 27, 2025
- Modified shareholder rights · Amended charter or bylaws · Other material eventAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- S-8FORM S-8May 13, 2026
- 10-QFORM 10-QMay 13, 2026
- 8-KMay 13, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- 4PRIMARY DOCUMENTMay 6, 2026
- EFFECTApr 15, 2026
- EFFECTApr 15, 2026
- CORRESPApr 13, 2026
- CORRESPApr 13, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.